

Manipulating Gut Microbiota: Innovative Applications of Probiotics in Food and Health Industry Transformation

Bhargav Parmar^a, Gayatri Patel^{b*} and Riteshkumar Arya^c.

^aResearch Scholar Mehsana Urban Institute of Science, Ganpat University, Mehsana, 384012, India.

^bAssistant Professor Mehsana Urban Institute of Science, Ganpat University, Mehsana, 384012, India.

^cDepartment of Clinical Microbiology & Infectious Diseases, All India Institute of Medical Sciences, Rajkot, Gujarat.

Abstract

Probiotics are live microorganisms that confer health benefits to the host when administered in adequate amounts and play a critical role in maintaining gut microbiota balance and overall health. This review summarizes recent advances in probiotic applications across the food and health industries, with emphasis on digestive, metabolic, immune, and mental health outcomes. Technological innovations such as microencapsulation, nanoencapsulation, smart polymers, and targeted delivery systems have significantly improved probiotic stability, viability, and functional efficacy. Emerging approaches, including next-generation probiotics, postbiotics, and synbiotics, offer promising avenues for precision nutrition and preventive healthcare. Despite these advances, several challenges remain, including strain-specific efficacy, loss of viability during processing and gastrointestinal transit, inter-individual variability in response, and inconsistent global regulatory frameworks. Addressing these limitations through robust clinical validation, personalized microbiome-based strategies, and harmonized regulations will be essential for broader clinical and industrial adoption. Overall, probiotics represent a transformative interface between nutrition and medicine, with growing potential to reshape functional foods and preventive health strategies.

Keywords: probiotics, gut microbiota, functional foods, health benefits, innovation, food technology

1. Introduction

The phrase "gut microbiota" describes the wide variety of microorganisms that live in the human gastrointestinal (GI) tract, including viruses, fungi, bacteria, and archaea. These microbial communities are essential for several physiological processes, such as vitamin synthesis, immune response modulation, intestinal barrier integrity maintenance, and nutrient absorption and digestion (Fan et al., 2021). Homeostasis requires a stable and diverse gut microbiota, but dysbiosis, or an imbalance in these microbial communities, has been linked to a number of chronic illnesses, including obesity, type 2 diabetes, inflammatory bowel disease (IBD), and neurological disorders, including Alzheimer's disease and depression (Chakravarty et al., 2024; Ugwu et al., 2024). Probiotics have drawn interest recently as a potentially effective way to alter gut microbiota and enhance general health. Probiotics are "live microorganisms which, when administered in adequate amounts, confer a health benefit on the host," according to the World Health Organization (Net et al., 2014a). These helpful microorganisms can work in a variety of ways, such as by inhibiting pathogens

competitively, improving mucosal barrier function, modifying the immune system, and producing bioactive metabolites like neurotransmitters and short-chain fatty acids (Abdul Manan, 2025). Due to growing consumer awareness and the need for natural and preventative health solutions, the food industry has swiftly integrated probiotics into a variety of functional foods and beverages. The goal of this study is to give a thorough overview of the composition of the gut microbiota, interactions between probiotics and their hosts, new developments in probiotic delivery systems, and the growing use of probiotics in the food and medical industries. According to the joint WHO/FAO definition, probiotics are "live microorganisms which, when administered in adequate amounts, confer a health benefit on the host" (FAO/WHO (2001) Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Acid Bacteria. Report of a Joint FAO/WHO Expert Consultation, Córdoba, Argentina. - References - Scientific Research Publishing, n.d.). This definition is used as the standard throughout this paper to avoid repetition. For clarity, terms such as designer

*Corresponding Author
E-mail address: gbp01@ganpatuniversity.ac.in

probiotics (engineered strains with targeted therapeutic functions), psychobiotics (probiotics influencing the gut–brain axis and mental health), and functional foods (foods providing health benefits beyond basic nutrition) are defined here and applied consistently in later sections. Although numerous studies support the role of probiotics in maintaining gut health and immunity, the evidence is not always consistent. Some randomized controlled trials have reported significant improvements in gastrointestinal disorders, while others show only modest or negligible benefits. These discrepancies often arise from differences in probiotic strains, variations in dosage and formulation, and short study durations. For example, *Lactobacillus*-based interventions may demonstrate benefits in antibiotic-associated diarrhea, whereas *Bifidobacterium* strains show variable efficacy depending on host age and underlying health conditions. Such conflicting findings underscore the importance of strain-specific validation and standardized clinical endpoints, which remain critical shortcomings in current probiotic research.

2. THE ROLE OF PROBIOTICS AND GUT MICROBIOTA

A diverse and dynamic population of bacteria known as the gut microbiota colonizes the human gastrointestinal tract. Six prominent bacterial phyla Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, Fusobacteria, and Verrucomicrobia make up the majority of this ecosystem (Hou et al., 2022). Of them, Firmicutes and Bacteroidetes make up over 90% of the gut microbiome and are essential for preserving immunological and metabolic balance. These microbial inhabitants perform a number of essential functions required for host physiology. They are important in the fermentation of indigestible dietary polysaccharides, which produces short-chain fatty acids (SCFAs) such as butyrate, propionate, and acetate. SCFAs have anti-inflammatory qualities, regulate gut pH, and give colonocytes energy. Additionally, the growth and regulation of the human immune system depend on the gut microbiota, which also produces essential vitamins including vitamin K and particular B vitamins (such as B12, riboflavin, and folate) (Latif et al., 2023). Dysbiosis, a disorder characterized by disruptions in the diversity or composition of the gut microbiota, has been linked to a number of illnesses, including obesity, metabolic syndrome, inflammatory bowel diseases, and neurodegenerative diseases like Parkinson's and Alzheimer's (Fan & Pedersen, 2021). Scientific interest in employing probiotics as a targeted strategy to support health and restore gut microbial balance has increased as a result of a better understanding of these interactions. Probiotics interact with the gut microbiota and host systems through a number of well-established pathways. The FAO/WHO defines probiotics as "live microorganisms which, when administered in adequate

amounts, confer a health benefit on the host" (Division, 2006). By vying for nutrients and adhesion sites on the intestinal mucosa and by generating antimicrobial compounds such as bacteriocins and organic acids, probiotic strains prevent the colonization and proliferation of harmful bacteria (Chandrasekaran et al., 2024). This competitive strategy promotes the development of a healthy microbial community and lowers the chance of illness. By increasing the synthesis of mucins, which act as a protective mucus layer, and by modifying tight junction proteins, which lower gut permeability, probiotics support the integrity of the epithelial barrier. This is essential to stop poisons and infections from moving into the bloodstream (Chandrasekaran et al., 2024). Probiotic strains that produce butyrate are especially well-known for their contribution to the preservation of mucosal health and barrier function. Both innate and adaptive immune responses are modulated as a result of probiotics' interactions with the gut-associated lymphoid tissue (GALT). While inhibiting pro-inflammatory mediators like TNF- α and IL-6, they can stimulate the release of anti-inflammatory cytokines (such as IL-10) and regulatory T cell responses (Rastogi et al., 2022a). This characteristic is particularly helpful for autoimmune and inflammatory conditions. In addition to SCFAs, probiotic strains generate a range of bioactive substances with antibacterial, antioxidant, and anti-inflammatory qualities, such as conjugated linoleic acid, hydrogen peroxide, and bacteriocins (Al-Habsi et al., 2024). In addition to having systemic impacts on immunity, metabolism, and even tumor suppression, these metabolites also affect the gut environment. According to new research, certain probiotic strains known as "psychobiotics" are involved in the production of neuroactive substances like dopamine, serotonin, and gamma-aminobutyric acid (GABA). Through the gut-brain axis, these neurotransmitters can alter brain activity, impacting stress reactions, emotion, and cognition (Vijayaram et al., 2024). This has created new opportunities for probiotic-based treatments for mental health conditions like depression and anxiety. All of these processes work together to support the many health advantages of probiotic use and support its use as a therapeutic adjuvant in both clinical and preventative settings. The composition of the gut microbiota provides the foundation for understanding host–microbe interactions and their role in maintaining health or contributing to disease. However, characterizing microbial communities alone is insufficient. To translate these insights into practical outcomes, it is necessary to examine how these microbial functions can be harnessed for clinical applications, particularly through the use of probiotics, prebiotics, and related interventions. Figure 1 illustrates the key factors influencing the diversity and composition of the human gut microbiota. These factors include stress, birth and feeding practices, medication, diet, geography, and age, all of which shape microbial colonization from infancy and continue to modulate the

microbiome throughout life. Individual variations in gut microbial communities are highlighted, emphasizing how

lifestyle, developmental, and environmental factors collectively impact microbiota composition.




Figure 1. Numerous elements that affect the diversity and makeup of the gut microbiota are depicted in the figure. Stress, birth and feeding practices, medication, food, location, and age are a few examples. From microbial colonization in infancy to continuous alterations throughout the human lifespan, every aspect influences the gut microbial ecosystem. The graphic highlights how individual variations in gut microbial communities are influenced by lifestyle, developmental, and environmental factors.

3. TECHNOLOGICAL INNOVATIONS IN PROBIOTIC DELIVERY

Due in large part to customer desire for dietary options that promote health, the functional food business has experienced exponential expansion. Plant-based substitutes made from soy, oats, and coconut, as well as dairy-based goods like yogurt, kefir, and cheese, have become important probiotic delivery systems (Gebeyehu & Gebeyehu, 2023). Through fermentation, these matrices not only operate as efficient transporters but also improve probiotic activity and survival. Fermentation creates bioactive compounds that complement probiotic activities and help break down complex nutrients, boosting bioavailability (Cui et al., 2024). Fermented foods help probiotics remain viable as they travel through the digestive system and over the course of their shelf life. Preserving microbial viability throughout processing, storage, and transit through the stomach's acidic environment is a major difficulty in the use of probiotics. Advanced encapsulation techniques, including microencapsulation and nanoencapsulation, have been

developed to overcome this. Using protective matrices such as alginate, chitosan, gelatine, or lipid-based carriers, these methods immobilize probiotics (Hemaiswarya et al., 2013). Encapsulation improves the stability and targeted release of probiotics in the colon by protecting them from environmental stresses such as heat, oxygen, and bile salts. The accuracy and effectiveness of distribution are further enhanced by newly developed smart delivery methods, such as pH-responsive and biofilm-based carriers (Abbas et al., 2022). The creation of next-generation probiotics has been completely transformed by advances in genetic and synthetic engineering. Researchers have created probiotic strains with improved functional characteristics, including resistance to bile and acid, the capacity to adhere, and the generation of particular beneficial chemicals, using gene editing and synthetic biology approaches (Hemaiswarya et al., 2013). Therapeutic compounds like anti-inflammatory cytokines or enzymes that break down toxins can be expressed by designer probiotics, providing tailored treatments for chronic illnesses. Applications in precision medicine, where probiotics are customized to each person's

microbiome and health requirements, are made possible by this frontier (Parvin & Sadras, 2024). Figure 2 illustrates the technological innovations enhancing probiotic delivery, including microencapsulation, smart polymers, 3D printing, and nanotechnology. These

approaches improve probiotic stability, targeted delivery, and survival through gastrointestinal transit, thereby increasing their efficacy in functional foods and therapeutic applications.




Figure 2. The picture shows how probiotics benefit from nanotechnology, smart polymers, 3D printing, and microencapsulation.

4. PROBIOTICS IN HEALTH INDUSTRY APPLICATIONS

Table 1. provides a summary of commonly used probiotic strains, their delivery methods, health targets, and mechanisms of action. This comparative overview highlights strain-specific benefits, aiding in clinical and functional food applications.

Probiotic Strain	Delivery Method	Targeted Health Outcomes	Mechanism of Action
<i>Lactobacillus rhamnosus</i>	Yogurt, capsules	Gut health, immune support	Enhances barrier function, modulates immune response, competitive exclusion of pathogens
<i>Bifidobacterium longum</i>	Fermented foods, powders	Digestive health, metabolic regulation	Produces SCFAs, reduces gut inflammation, modulates microbiota composition
<i>Lactobacillus acidophilus</i>	Dairy products, capsules	Lactose digestion, gastrointestinal comfort	Produces lactic acid, lowers intestinal pH, inhibits pathogenic bacteria
<i>Saccharomyces boulardii</i>	Capsules	Antibiotic-associated diarrhea, IBD	Modulates immune response, stabilizes gut microbiota, competes with pathogens

Probiotic Strain	Delivery Method	Targeted Health Outcomes	Mechanism of Action
<i>Akkermansia muciniphila</i>	Next-generation probiotics (NGPs)	Obesity, metabolic disorders	Mucin degradation, improves gut barrier, anti-inflammatory effects
<i>Faecalibacterium prausnitzii</i>	NGP formulations, encapsulation	Anti-inflammatory, metabolic health	Produces butyrate, modulates immune system, strengthens epithelial barrier
Synbiotics (probiotic + prebiotic)	Capsules, functional foods	Gut health, metabolic support, immune modulation	Promotes colonization, enhances SCFA production, synergistic modulation of microbiota

Building upon the characterization of microbiota composition, the next step is to explore how these microbial dynamics can be applied in clinical practice. Probiotics, postbiotics, and synbiotics represent targeted strategies that leverage our understanding of microbial ecology to improve health outcomes, offering potential interventions for gastrointestinal disorders, immune modulation, and beyond. Probiotics are well known for their ability to help treat gastrointestinal diseases and have long been linked to gut health. According to clinical and experimental research, they are effective in lessening the intensity and recurrence of antibiotic-associated diarrhea (AAD), irritable bowel syndrome (IBS), and inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis (Tan et al., 2021). These advantages, which are mostly strain-specific, include improved mucosal barrier integrity, gut microbiota balance, and intestinal inflammatory control. *Bifidobacterium longum* and *Lactobacillus rhamnosus* GG, for example, have demonstrated potential in enhancing mucosal healing and lowering levels of pro-inflammatory cytokines (Rastogi & Singh, 2022). The function of probiotics in controlling cardiovascular and metabolic health is becoming more widely acknowledged. The pathophysiology of obesity, type 2 diabetes mellitus (T2DM), and cardiovascular illnesses is influenced by lipid metabolism, insulin resistance, and systemic inflammation, all of which can be modulated by a number of strains (Wang et al., 2025). *Bifidobacterium breve* and *Lactobacillus plantarum*, for instance, have been shown to have lipid-lowering qualities, while other bacteria improve glycemic management and glucose absorption by modifying gut-derived compounds such as SCFAs. Probiotics interact with gut-associated lymphoid tissue (GALT) to produce notable immunomodulatory effects. They lower the risk of allergic reactions, infections, and autoimmune flare-ups by promoting the differentiation of regulatory T cells, increasing mucosal immunity, and improving the production of anti-inflammatory cytokines (e.g., IL-10) (Rastogi et al., 2022b). Several probiotic strains have the ability to improve the effectiveness of vaccines and lessen

the severity of respiratory tract infections, highlighting their potential as adjuvants for the immune system. Recent developments in the study of the microbiome have revealed the significant impact that probiotics have on mental health through the gut-brain axis. These so-called "psychobiotics" have the ability to produce neuroactive substances that impact mood and cognitive function, including dopamine, serotonin, and gamma-aminobutyric acid (GABA) (Zeng et al., 2025). Certain strains, such as *Lactobacillus helveticus* and *Bifidobacterium infantis*, have been shown in clinical research to reduce the symptoms of stress-related illnesses, anxiety, and depression. Probiotics may also lessen hyperactivation of the hypothalamic-pituitary-adrenal (HPA) axis, a crucial stress response mechanism. Figure 3 depicts the primary health benefits of probiotics, highlighting their roles in digestive health, immune support, skin health, and mental wellness. The figure provides a concise visual summary of the systemic effects of probiotic intake, emphasizing their multifunctional contributions to human well-being.




Figure 3. The picture shows the primary health advantages of probiotics, which include immunological support, skin health, mental wellness, and digestive health.

4. PROBIOTICS IN HEALTH INDUSTRY APPLICATIONS

Table 2. Comparative overview of probiotic regulations across regions.

Region	Regulatory Authority	Definition / Classification	Approval Process	Labelling & Claims	Notes
United States	Food and Drug Administration (FDA); DSHEA	Classified as <i>dietary supplements</i> or <i>GRAS</i>	No premarket approval for supplements; GRAS requires safety evidence	FDA evaluation for health claims; structure–function claims allowed w/ disclaimer	More flexible vs. EU
European Union	European Food Safety Authority (EFSA)	No legal definition; treated as <i>novel foods/supplements</i>	Requires EFSA scientific opinion and authorization	Very strict; almost no probiotic health claim approved	Most stringent regulatory system
Japan (Asia-Pac)	Ministry of Health, Labour & Welfare; Foods for Specified Health Uses (FOSHU)	Classified under <i>functional foods</i> (FOSHU)	Clinical and safety data submission required	Health claims allowed if scientifically validated	Structured, supportive of functional foods
India (Asia-Pac)	Food Safety and Standards Authority of India (FSSAI)	Classified as <i>nutraceuticals/functional foods</i>	Requires safety, efficacy, and strain-specific documentation	Health claims allowed with FSSAI approval	Growing market, regulations improving
China (Asia-Pac)	National Health Commission; State Administration for Market Regulation	Classified as <i>functional foods/health foods</i>	Premarket registration with safety and efficacy data	Functional claims permitted with scientific evidence	Large market, expanding research
Australia / NZ	Food Standards Australia	Classified as <i>novel</i>	Requires premarket safety assessment	Claims allowed if supported	Aligned with food safety &
	New Zealand (FSANZ)	<i>foods/supplements</i>		by scientific evidence	supplement law

Many strains of probiotics are categorized as "Generally Recognized as Safe" (GRAS) in the US, indicating that they are generally considered safe for human ingestion. The regulatory environment surrounding probiotic goods, however, differs greatly between nations and areas, which affects customer confidence as well as market accessibility. The Dietary Supplement Health and Education Act (DSHEA) of 1994 is the main law governing probiotics in the US. As long as probiotics aren't meant to be used to diagnose, treat, cure, or prevent any disease, this rule permits their marketing as dietary supplements without the Food and Drug Administration's (FDA) previous approval. Any health claims must be backed up by reliable scientific data, and manufacturers are in charge of making sure their goods are safe and accurately labelled. Probiotics, however, are exempt from the stringent pre-market approval procedure needed for medicines since they are not categorized as drugs (Net et al., 2014b; Sanders et al., 2019). The European Food Safety Authority (EFSA) of the European Union, on the other hand, takes a more stringent stance. Before probiotic products can be sold, the EFSA requires that any health claims be thoroughly supported by science. Since there isn't enough proof of cause-and-effect links, the EFSA has rejected a number of probiotic-related claims to date. This highlights the necessity of strain-specific, placebo-controlled human clinical trials to confirm any potential benefits (Ray & Montet, 2017). Marketing in the EU market is more complicated because the EFSA has prohibited the use of the term "probiotic" on product labelling unless the claim satisfies its strict scientific standards. The international trade and standardization of probiotic goods are hampered by these regulatory discrepancies between international organizations. Harmonizing probiotic laws is therefore becoming more and more necessary to promote international trade and boost customer trust in the effectiveness and safety of

products (Morelli & Capurso, 2012). Commercially speaking, the probiotics business is growing quickly worldwide due to rising consumer knowledge of immunity, gut health, and overall wellbeing. The need for probiotic-enriched functional meals and supplements has been further supported by the increase in the prevalence of chronic diseases and the move toward preventative healthcare practices. The global probiotic market is expected to reach USD 75 billion by 2025, according to recent industry predictions, with notable increase seen in North America, Europe, and Asia-Pacific (Bustos et al., 2024). The use of probiotics in plant-based food matrices, dairy products, infant formulae, and tailored nutrition, as well as developments in biotechnology, are further driving this expansion. Clearer international regulatory frameworks, investments in top-notch clinical research, and open consumer education regarding the safety, effectiveness, and strain-specific activities of probiotic products are essential to maintaining current market momentum. To provide a broader international perspective, this review includes regulatory and market comparisons beyond the US and EU, encompassing Asia-Pacific countries such as Japan, India, China, and Australia/New Zealand. The inclusion of these regions highlights differences in classification, approval processes, labeling requirements, and consumer trends, offering a more comprehensive understanding of global probiotic applications. Additionally, clinical and preventive health strategies from these regions are considered, illustrating diverse approaches to probiotic integration in functional foods and therapeutic interventions. Figure 4 illustrates the expanding trends in the probiotics industry alongside key regulatory requirements. It highlights the variations in national regulations across regions and demonstrates how increasing consumer awareness and demand are driving market growth.




Figure 4. The picture shows the probiotics industry's expanding patterns and regulatory requirements, highlighting how national regulations vary and how customer demand is fueling market expansion.

6. CHALLENGES AND FUTURE PERSPECTIVES

Probiotics are becoming more and more well-known worldwide because of their possible health advantages, but a number of serious issues still prevent them from being consistently effective, scalable, and compliant with regulations. Food preparation, storage, and gastrointestinal transit all reduce microbial viability, which is one of the biggest challenges in probiotic creation. Before they reach the intestinal system, probiotic strains may lose some of their effectiveness due to environmental factors such as oxygen exposure, temperature changes, wetness, and the stomach's acidity (Abbas et al., 2022). Although technologies like microencapsulation, cooling, and freeze-drying have been developed to increase the survival of these microbes, not all probiotic strains react equally to these preservation strategies. The strain specificity of probiotics is another significant drawback. Different strains of the same microbial species can have wildly diverse impacts on the host. Thus, it is not possible to extrapolate health benefits seen with one strain to others (Gibson et al., 2017). Thorough strain-level identification, carefully planned clinical trials, and precise product labelling are required for this specificity. Without these safeguards, products can produce inconsistent results or make unsupported health claims, which would erode consumer confidence and scientific legitimacy. Last but not least, the worldwide probiotic business faces significant challenges due to regulatory complexity. Countries' regulatory frameworks differ greatly from one another. In contrast to the United States, where probiotics are categorized as dietary supplements and subject to the more permissive Dietary Supplement Health and Education Act (DSHEA), the European Food Safety Authority (EFSA) requires strong scientific evidence to support any health claims pertaining to probiotics (Akutko & Stawarski, 2021; El Sheikha & Ray, 2017). International commercialization, product standardization, and the creation of generally recognized standards for probiotic efficacy and safety are all hampered by these uneven regulatory requirements. Novel scientific approaches are being developed to improve the accessibility, personalization, and functional performance of probiotic therapies in response to the issues surrounding probiotic efficacy, stability, and regulation. The advent of next-generation probiotics (NGPs), which contain recently discovered gut commensals like *Faecalibacterium prausnitzii* and *Akkermansia muciniphila*, is one example of this development. These anaerobic microbes have shown great promise in regulating host metabolism and immunological responses, in contrast to conventional probiotic strains like *Lactobacillus* and *Bifidobacterium*. Research has connected them to better metabolic health and anti-inflammatory properties, especially when it comes to diseases like inflammatory bowel disease, type 2 diabetes, and obesity (Cani & de Vos, 2017; Murali & Mansell, 2024). The development of customized probiotics is

another exciting field, enabled by developments in big data analytics, artificial intelligence, and metagenomic sequencing. With the aid of these technologies, scientists may examine a person's microbiome profile and create customized probiotic treatments that target particular dysbiosis patterns. When it comes to treating metabolic, gastrointestinal, and neurocognitive diseases, customized formulas may provide better results (Turrone et al., 2014; Zeevi et al., 2015). Postbiotics and synbiotics are becoming more well-known due to their stability and potential for therapeutic use. Particularly for people with impaired immune systems, postbiotics—which are made up of inactivated microbial cells or their bioactive metabolic byproducts—provide a safer substitute for live probiotics. Through synergistic interactions, synbiotics—which include probiotics and prebiotics—strive to improve microbial viability and colonization, ultimately leading to better host health outcomes (Aguilar-Toalá et al., 2018; Markowiak & Ślizewska, 2017). Current literature also leaves several information gaps unaddressed. Few studies have explored the economic feasibility of probiotic interventions, particularly in low- and middle-income regions where accessibility and affordability are crucial. Moreover, research is heavily skewed toward Western populations, leaving non-Western microbiome dynamics underexplored. Technological innovations such as microencapsulation, genome editing, and bioinformatics-driven personalization may address some of the challenges of strain viability and host variability, yet their clinical translation remains limited. Addressing these gaps will require harmonized regulatory standards, strain-specific clinical validation, and integrative studies that consider both biological efficacy and socio-economic dimensions. To strengthen the discussion on emerging fields, additional focus has been placed on postbiotics and synbiotic. Postbiotics, defined as non-viable microbial cells or their metabolites that confer health benefits, offer advantages in terms of stability, safety, and ease of formulation compared to live probiotics. However, their clinical significance is still being clarified, as large-scale human trials remain limited, and their mechanisms of action require deeper exploration. Economically, postbiotics hold promise for reducing production costs and expanding applications in immunocompromised populations, where live microorganisms may pose risks. Similarly, synbiotic—combinations of probiotics and prebiotics—are designed to enhance microbial colonization and functional outcomes. While clinical evidence supports their role in improving digestive health, their efficacy varies depending on strain-prebiotic compatibility, dosage, and host microbiome diversity. Despite these limitations, synbiotics are gaining increasing industrial interest due to their market potential in functional foods and personalized nutrition. By expanding the future perspectives section with these considerations, the paper not only highlights the promise of these emerging approaches but also

critically acknowledges their scientific, clinical, and economic challenges, thereby offering a more balanced and forward-looking outlook.

7. CONCLUSION

With its many advantages that go beyond gut health to include immunological regulation, metabolic balance, and mental well-being, probiotics continue to be a promising new development in both nutrition and medicine. Their increasing use in functional meals and treatment plans demonstrates the move toward preventative and individualized care. Important restrictions on the viability and specificity of probiotics are being addressed by technological advancements including genome editing, microencapsulation, and bioinformatics-driven customisation. A new era in microbiome-targeted treatments is being ushered in by the development of next-generation probiotics and postbiotics. Probiotics are positioned to be a key component of future health strategies as scientific research continues to clarify the intricate relationships between bacteria and human physiology and as worldwide regulatory frameworks become more uniform. Realizing the full promise of probiotics as long-lasting and potent agents for enhancing global health will require sustained investment in top-notch clinical research, consumer education, and regulatory clarity. Beyond gastrointestinal health, probiotics have been investigated for their role in

metabolic regulation, mental wellness, and dermatological conditions. The literature in these areas is marked by significant disputes. While certain studies suggest psychobiotics can influence mood and cognition through gut–brain signalling, others report minimal impact due to high interindividual variability in microbiome responses. Similarly, evidence linking probiotics to long-term metabolic improvements remains inconclusive, with some trials noting reductions in obesity-related markers and others finding no measurable effects. These disputes reveal both the promise and uncertainty of probiotic applications beyond the gut, highlighting the urgent need for more rigorous, large-scale, and long-term clinical trials. While probiotics have demonstrated wide-ranging benefits, several areas still require deeper investigation to realize their full potential. Future research must focus on large-scale, long-term clinical trials to validate strain-specific effects, the development of cost-effective delivery systems to ensure viability, and the integration of omics and artificial intelligence for personalized interventions. Furthermore, harmonization of global regulatory standards and greater exploration of emerging fields such as next-generation probiotics, postbiotics, and synbiotics will be essential. By emphasizing these future directions, the conclusion provides a more forward-looking perspective that underscores both the opportunities and challenges shaping the next phase of probiotic science and application.

REFERENCES

- Abbas, M. S., Saeed, F., Afzaal, M., Jianfeng, L., Hussain, M., Ikram, A., & Jabeen, A. (2022). Recent trends in encapsulation of probiotics in dairy and beverage: A review. *Wiley Online Library*, 46(7). <https://doi.org/10.1111/JFPP.16689>
- Abdul Manan, M. (2025). Progress in Probiotic Science: Prospects of Functional Probiotic-Based Foods and Beverages. *International Journal of Food Science*, 2025(1), 5567567. <https://doi.org/10.1155/IJFO/5567567>
- Aguilar-Toalá, J. E., Garcia-Varela, R., Garcia, H. S., Mata-Haro, V., González-Córdova, A. F., Vallejo-Cordoba, B., & Hernández-Mendoza, A. (2018). Postbiotics: An evolving term within the functional foods field. *Trends in Food Science & Technology*, 75, 105–114. <https://doi.org/10.1016/J.TIFS.2018.03.009>
- Akutko, K., & Stawarski, A. (2021). Probiotics, Prebiotics and Synbiotics in Inflammatory Bowel Diseases. *Journal of Clinical Medicine* 2021, Vol. 10, Page 2466, 10(11), 2466. <https://doi.org/10.3390/JCM10112466>
- Al-Habsi, N., Al-Khalili, M., Haque, S. A., Elias, M., Olqi, N. Al, & Al Uraimi, T. (2024). Health Benefits of Prebiotics, Probiotics, Synbiotics, and Postbiotics. *Nutrients*, 16(22), 3955. <https://doi.org/10.3390/NU16223955>
- Bustos, A. Y., Taranto, M. P., Gerez, C. L., Agriopoulou, S., Smaoui, S., Varzakas, T., & Enshasy, H. A. El. (2024). Recent Advances in the Understanding of Stress Resistance Mechanisms in Probiotics: Relevance for the Design of Functional Food Systems. *Probiotics and Antimicrobial Proteins*, 17(1), 138–158. <https://doi.org/10.1007/S12602-024-10273-9/FIGURES/2>
- Cani, P. D., & de Vos, W. M. (2017). Next-generation beneficial microbes: The case of *Akkermansia muciniphila*. *Frontiers in Microbiology*, 8(SEP), 2925252. <https://doi.org/10.3389/FMICB.2017.01765/BIBTEX>
- Chakravarty, K., Gaur, S., Kumar, R., Jha, N. K., & Gupta, P. K. (2024). Exploring the multifaceted therapeutic potential of probiotics: a review of current insights and applications. Springer. <https://doi.org/10.1007/S12602-024-10328-X>
- Chandrasekaran, P., ... S. W.-I. journal of, & 2024, undefined. (2024). Effects of probiotics on gut microbiota: an overview. *Mdpi.ComP*

- Chandrasekaran, S Weiskirchen, R
WeiskirchenInternational Journal of Molecular
Sciences, 2024•mdpi.Com.
<https://doi.org/10.3390/ijms25116022>
- Cui, R., Zhang, C., Pan, Z. H., Hu, T. G., & Wu, H. (2024). Probiotic-fermented edible herbs as functional foods: A review of current status, challenges, and strategies. Wiley Online Library, 23(2). <https://doi.org/10.1111/1541-4337.13305>
 - Division, N. (2006). Probiotics in food. <https://openknowledge.fao.org/handle/20.500.14283/a0512e>
 - El Sheikha, A. F., & Ray, R. C. (2017). Potential impacts of bioprocessing of sweet potato: Review. Critical Reviews in Food Science and Nutrition, 57(3), 455–471. <https://doi.org/10.1080/10408398.2014.960909>
 - Fan, Y., Microbiology, O. P.-N. R., & 2021, undefined. (2021). Gut microbiota in human metabolic health and disease. Nature.Com. <https://doi.org/10.1038/s41579-020-0433-9>
 - Fan, Y., & Pedersen, O. (2021). Gut microbiota in human metabolic health and disease. Nature Reviews Microbiology, 19(1), 55–71. <https://doi.org/10.1038/S41579-020-0433-9>;SUBJMETA
 - FAO/WHO (2001) Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Acid Bacteria. Report of a Joint FAO/WHO Expert Consultation, Córdoba, Argentina. - References - Scientific Research Publishing. (n.d.). Retrieved October 6, 2025, from <https://www.scirp.org/reference/referencespapers?referenceid=1456307>
 - Gebeyehu, M. N., & Gebeyehu, M. N. (2023). Recent Advances and Application of Biotechnology in the Dairy Processing Industry: A Review. Intensive Animal Farming - A Cost-Effective Tactic. <https://doi.org/10.5772/INTECHOPEN.105859>
 - Gibson, G. R., Hutkins, R., Ellen Sanders, M., Prescott, S. L., Reimer, R. A., Salminen, S. J., Scott, K., Stanton, C., Swanson, K. S., Cani, P. D., Verbeke, K., & Reid, G. (2017). Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. <https://doi.org/10.1038/nrgastro.2017.75>
 - Hemaiswarya, S., Raja, R., Ravikumar, R., & Carvalho, I. S. (2013). Mechanism of action of probiotics. Brazilian Archives of Biology and Technology, 56(1), 113–119. <https://doi.org/10.1590/S1516-89132013000100015>
 - Hou, K., Wu, Z.-X., Chen, X.-Y., Wang, J.-Q., Zhang, D., Xiao, C., Zhu, D., Koya, J. B., Wei, L., Li, J., & Chen, Z.-S. (2022). Microbiota in health and diseases. Nature.ComK Hou, ZX Wu, XY Chen, JQ Wang, D Zhang, C Xiao, D Zhu, JB Koya, L Wei, J Li, ZS ChenSignal Transduction and Targeted Therapy, 2022•nature.Com. <https://doi.org/10.1038/s41392-022-00974-4>
 - Latif, A., Shehzad, A., Niazi, S., Zahid, A., Ashraf, W., Iqbal, M. W., Rehman, A., Riaz, T., Aadil, R. M., Khan, I. M., Özogul, F., Rocha, J. M., Esatbeyoglu, T., & Korma, S. A. (2023). Probiotics: mechanism of action, health benefits and their application in food industries. Frontiersin.Org, 14. <https://doi.org/10.3389/FMICB.2023.1216674/FULL>
 - Markowiak, P., & Ślizewska, K. (2017). Effects of Probiotics, Prebiotics, and Synbiotics on Human Health. Nutrients 2017, Vol. 9, Page 1021, 9(9), 1021. <https://doi.org/10.3390/NU9091021>
 - Morelli, L., & Capurso, L. (2012). FAO/WHO guidelines on probiotics: 10 years later. Journal of Clinical Gastroenterology, 46(SUPPL. 1). <https://doi.org/10.1097/MCG.0B013E318269FDD5>
 - Murali, S. K., & Mansell, T. J. (2024). Next generation probiotics: Engineering live biotherapeutics. Biotechnology Advances, 72, 108336. <https://doi.org/10.1016/J.BIOTECHADV.2024.108336>
 - Net, M. E. S. M., Hill, C., Guarner, F., Reid, G., Gibson, G. R., Merenstein, D. J., Pot, B., Morelli, L., Canani, R. B., Flint, H. J., Salminen, S., Calder, P. C., & Sanders, M. E. (2014a). The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature.ComC Hill, F Guarner, G Reid, GR Gibson, DJ Merenstein, B Pot, L Morelli, RB Canani, HJ FlintNature Reviews Gastroenterology & Hepatology, 2014•nature.Com, 11, 506–514. <https://doi.org/10.1038/nrgastro.2014.66>
 - Net, M. E. S. M., Hill, C., Guarner, F., Reid, G., Gibson, G. R., Merenstein, D. J., Pot, B., Morelli, L., Canani, R. B., Flint, H. J., Salminen, S., Calder, P. C., & Sanders, M. E. (2014b). The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature.ComC Hill, F Guarner, G Reid, GR Gibson, DJ Merenstein, B Pot, L Morelli, RB Canani, HJ FlintNature Reviews Gastroenterology & Hepatology, 2014•nature.Com, 11, 506–514. <https://doi.org/10.1038/nrgastro.2014.66>
 - Parvin, T., & Sadras, S. R. (2024). Advanced probiotics: Bioengineering and their therapeutic application. Springer, 51(1). <https://doi.org/10.1007/S11033-024-09309-8>

- Rastogi, S., & Singh, A. (2022). Gut microbiome and human health: Exploring how the probiotic genus *Lactobacillus* modulate immune responses. *Frontiers in Pharmacology*, 13, 1042189. <https://doi.org/10.3389/FPHAR.2022.1042189/XML/NLM>
- Rastogi, S., Singh, A., De, S., Soares, C., & Bezirtoglou, E. (2022a). Gut microbiome and human health: Exploring how the probiotic genus *Lactobacillus* modulate immune responses. *Frontiersin.OrgS Rastogi, A SinghFrontiers in Pharmacology*, 2022•frontiersin.Org, 13, 1042189. <https://doi.org/10.3389/FPHAR.2022.1042189/FULL>
- Rastogi, S., Singh, A., De, S., Soares, C., & Bezirtoglou, E. (2022b). Gut microbiome and human health: Exploring how the probiotic genus *Lactobacillus* modulate immune responses. *Frontiersin.OrgS Rastogi, A SinghFrontiers in Pharmacology*, 2022•frontiersin.Org, 13, 1042189. <https://doi.org/10.3389/FPHAR.2022.1042189/FULL>
- Ray, R., & Montet, D. (2017). Fermented Foods, Part II: Technological Interventions. [https://books.google.com/books?hl=en&lr=&id=5zYlDwAAQBAJ&oi=fnd&pg=PA1988&dq=Technological+trends+and+advancements+in+the+dairy+industry.+In+R.+C.+Ray+%26+D.+Montet+\(Eds.\)&ots=1HrAOrAl6l&sig=5E2PAzfCfaQ7ZbYcSyGu9AfSx4o](https://books.google.com/books?hl=en&lr=&id=5zYlDwAAQBAJ&oi=fnd&pg=PA1988&dq=Technological+trends+and+advancements+in+the+dairy+industry.+In+R.+C.+Ray+%26+D.+Montet+(Eds.)&ots=1HrAOrAl6l&sig=5E2PAzfCfaQ7ZbYcSyGu9AfSx4o)
- Sanders, M. E., Merenstein, D. J., Reid, G., Gibson, G. R., & Rastall, R. A. (2019). Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. *Nature Reviews Gastroenterology & Hepatology* 2019 16:10, 16(10), 605–616. <https://doi.org/10.1038/s41575-019-0173-3>
- Tan, A. H., Hor, J. W., Chong, C. W., & Lim, S. Y. (2021). Probiotics for Parkinson's disease: Current evidence and future directions. *JGH Open*, 5(4), 414–419. <https://doi.org/10.1002/JGH3.12450>
- Turróni, F., Ventura, M., Buttó, L. F., Duranti, S., O'Toole, P. W., Motherway, M. O. C., & Van Sinderen, D. (2014). Molecular dialogue between the human gut microbiota and the host: A *Lactobacillus* and *Bifidobacterium* perspective. *Cellular and Molecular Life Sciences*, 71(2), 183–203. <https://doi.org/10.1007/S00018-013-1318-0/METRICS>
- Ugwu, O., Alum, E., Okon, M., Medicine, E. O., & 2024, undefined. (2024). Mechanisms of microbiota modulation: Implications for health, disease, and therapeutic interventions. *Journals.Lww.Com. https://journals.lww.com/md-journal/fulltext/2024/05100/mechanisms_of_microbiota_modulation__implications.28.aspx?context=latestarticles*
- Vijayaram, S., Sinha, R., Faggio, C., Ringø, E., & Chou, C. C. (2024). Biopolymer encapsulation for improved probiotic delivery: Advancements and challenges. *AIMS Microbiology*, 10(4), 986. <https://doi.org/10.3934/MICROBIOL.2024043>
- Wang, X., Wei, Z., Xiang, Q., Tang, L., & Xie, W. (2025). Therapeutic Potential of Probiotics in Metabolic Dysfunction-Associated Steatohepatitis: A Comprehensive Review. *Microorganisms* 2025, Vol. 13, Page 1894, 13(8), 1894. <https://doi.org/10.3390/MICROORGANISMS13081894>
- Zeevi, D., Korem, T., Zmora, N., Israeli, D., Rothschild, D., Weinberger, A., Ben-Yacov, O., Lador, D., Avnit-Sagi, T., Lotan-Pompan, M., Suez, J., Mahdi, J. A., Matot, E., Malka, G., Kosower, N., Rein, M., Zilberman-Schapira, G., Dohnalová, L., Pevsner-Fischer, M., ... Segal, E. (2015). Personalized Nutrition by Prediction of Glycemic Responses. *Cell*, 163(5), 1079–1094. <https://doi.org/10.1016/J.CELL.2015.11.001/ATTACHMENT/DB5FA69F-B523-44EA-A641-335223559222/MMC3.PDF>
- Zeng, Q., Li, P., Wu, H., Zhuang, Y., Zhang, Y., Asemani, S., Jamilian, P., Jamali, M., & Yu, H. (2025). Probiotics and gastrointestinal disorders: an umbrella meta-analysis of therapeutic efficacy. *European Journal of Medical Research* 2025 30:1, 30(1), 1–16. <https://doi.org/10.1186/S40001-025-02788-W>

